Alpha Cognition Inc (ACOG)
NASDAQ:ACOG
ACOG Stock Chart & Stats
$6.49
<$0.01(0.02%)
At close: 4:00 PM EST
$6.49
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$3.97 - $11.54
Previous Close$5.43
Volume265.46K
Average Volume (3M)87.53K
Market Cap
$129.99M
Enterprise Value$34.69M
Total Cash (Recent Filing)$66.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding21,774,103
10 Day Avg. Volume111,240
30 Day Avg. Volume87,535
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.84
Price to Sales (P/S)11.24
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue3.39
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$18.00Price Target Upside177.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.36
Revenue Forecast (FY)$24.25M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence ProgramPlanned real-world and Phase 4 studies focused on tolerability, dosing, and effectiveness could generate data to support regulatory discussions and increase physician confidence.
Commercial AdoptionBroadening prescriber base and expanding use in long-term care settings are driving sales traction for ZUNVEYL and supporting revenue growth prospects.
New Formulation PotentialA sublingual formulation in development for patients with swallowing difficulties could expand the addressable market and provide upside beyond current analyst forecasts if approved.
Bears Say
Competitive And Dilution RiskGreater-than-expected competition, potential clinical setbacks, and medium-to-long-term dilution risks could compress margins and reduce shareholder value.
Launch Execution RiskInability to launch ZUNVEYL in an optimized or timely manner could delay revenue realization and weaken investor sentiment.
Pricing And Payer ResistancePricing pressure or payer pushback could slow market uptake and limit patient access, constraining sales growth despite clinical interest.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $3.97 and its highest was $11.54 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $129.99M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Jun 02, 2026 which is in 48 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Mar 26, 2026. The company reported -$0.315 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.045.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,774,103 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.315 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -4.869%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (177.35% Upside)
$18.00 (177.35% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.51%
12-Months-Change
Fundamentals
Return on Equity
-125.65%
Trailing 12-Months
Asset Growth
820.85%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a positive operational momentum around ZUNVEYL: accelerating demand (62% QoQ bottle growth), significant repeat usage (82% repeat home orders; 69% repeat prescribers), two national PBM contracts, strong tolerability signals, active RWE and formulation programs, and a solid cash position (~$66M) supporting runway into 2027. Offsetting these positives are substantial and increasing operating expenses, widening operating losses, modest absolute revenue to date ($10.2M FY2025), and payer access still limiting broad patient uptake. Overall, the company appears to be in a high-investment, early-launch phase with clear commercialization execution and evidence-generation plans in place, and management projects a path to operating profitability in 2027.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$18.00
▲(177.35% Upside)
Technical Analysis
Sangamo Therapeutics
―
Elicio Therapeutics
―
Cognition Therapeutics
―
Lucid Diagnostics
―
Nuvectis Pharma
―
Ownership Overview
17.46% Insiders
0.06% Mutual Funds
42.72% Other Institutional Investors
39.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---